Peier 13 surprised Pfizer with a 87% increase in sales in the second quarter

Source: Biovalley, August 4, 2015, vaccine may be the most familiar biomedical product It is because of the wide application of this product that a large market with hundreds of billions of scale has emerged today, and it has become the big cake that the major biomedical companies hope to swallow Recently, Pfizer's vaccine Division has blossomed because of its best-selling pneumonia vaccine, Peier 13 Previously, according to a recent report released by evaluate Pharma, a world-renowned pharmaceutical market research institution, Pfizer's pneumonia vaccine prevnar 13 will remain the world's best-selling vaccine product by 2020 Last year, the Agency predicted that prevnar 13's sales in 2020 will be 60.8% US $billion, down to US $5.83 billion in this report Recently, Pfizer further released financial reports that the sales volume of the world's best-selling vaccine reached US $1.58 billion in the second quarter of 2015, an increase of 87% compared with the same period last year What's more, with the strong performance of Peier 13, the performance of Pfizer vaccine Department increased by 44% It can be said that Peier 13 is a veritable cash cow of Pfizer According to the analysis, one of the reasons for the strong demand growth of the vaccine product is that the CDC of the United States listed it as the recommended vaccination for people over 65 years old last August As we all know, with the process of aging society, the size of this age group may continue to increase by about 4 million in the next two years No wonder the previous investigation indicated that Pei 13 will dominate the world vaccine market in 2020 Pfizer is obviously not satisfied with their achievements It is understood that the company is actively lobbying for the support of the other six G7 countries (including Canada, France, Germany, Italy, the United Kingdom, Japan and the United States) According to bourla, head of Pfizer's vaccine division, the market size will probably be more than twice the size of the US market The outstanding performance of Peier 13 vaccine also reflects Pfizer's strong support for vaccine sector in recent years The company has invested heavily in recent years to expand the strength of the Department Pfizer first spent $635 million to acquire Baxter's vaccine business, and then put GlaxoSmithKline and two meningitis vaccines into the bag for $130 million Not long ago, the company acquired redvax of Switzerland Pfizer's focus on the vaccine business is clear At present, Pfizer's vaccine department is still under intense work, and the company is expanding the application age of Peier 13 vaccine to various age groups In addition, the scientists are also carrying out the second phase clinical research of tumor vaccine It can be predicted that Pfizer's vaccine department will further develop in the future.